ACCELERATE Peanut Study
Have you or your teen been diagnosed with a severe peanut allergy?
Have you been to an Emergency Department with a severe allergic reaction/anaphylaxis to peanuts?
Have you been prescribed an adrenaline autoinjector (EpiPen or Anapen)?
If so, you may be eligible to participate in a new research study.
You may be eligible for a new IgGenix study in Australia exploring whether an injectable antibody can help treat peanut allergy in teens and adults.
Find out more at iggenix.com.au
View the study brochure here.
Now enrolling: the OCEAN study for adults with eosinophilic granulomatosis with polyangiitis (EGPA)
The OCEAN clinical research study is looking for participants who are 18 years of age or older with eosinophilic granulomatosis with polyangiitis (EGPA). Study doctors are testing an investigational drug given as injections to find out if it works and to determine its safety in patients with EGPA.
What should I know about the OCEAN study?• To be eligible for this study, participants must: o Be at least 18 years of age or older o Have EGPA that has worsened or returned after previous treatment o Be currently taking a corticosteroid or immunosuppressant (your doctor will let you know if you may be eligible based on your current therapy)• This study will consist of 17 visits over a period of up to 52 weeks plus a follow-up phone call at 56 weeks• Participants will receive either the investigational drug (depemokimab) or an approved drug (mepolizumab) during the study while continuing their usual medications• The health and safety of participants will be monitored throughout the study• Participant data and information will be kept confidential • Study participants will receive all study-related procedures and the study drug at no cost
To learn more about the OCEAN study, please visit www.gskoceanclinicaltrial.com.
To learn more about the OCEAN study, please visit www.gskoceanclinicaltrial.com.
The CROSSING study for adults and adolescents with EoE
The CROSSING clinical research study is evaluating the safety and efficacy of tezepelumab for the treatment of Eosinophilic Esophagitis (EoE) in patients between 12 and 80 years of age.
To learn more about participating in the study you can visit the website https://eoetrialandyou.com/AusEE or call 1800948052 (Australia) / 0800441902 (New Zealand).
Eupraxia Pharmaceuticals Clinical Study
Do you have pain and difficulty with swallowing?
You might be eligible to participate in a clinical trial.
Eosinophilic Esophagitis (EoE) is a condition of the esophagus (tube from your mouth to stomach) that can lead to difficulty swallowing and causing food to get stuck in your throat while swallowing. A type of white blood cell, called an eosinophil, builds up in the lining of your esophagus and causes inflammation. Eupraxia Pharmaceuticals is conducting a clinical study to test a new treatment called EP-104IAR which has been formulated as an injection into the esophagus aimed to help those experiencing these symptoms of EoE.
Who is eligible:Male and female patients of age 18 years to 75 years old who have been diagnosed with Eosinophilic Esophagitis and have active symptoms of Eosinophilic Esophagitis.
Participation details:• There is no cost to participate• This clinical trial is being run by Dr Nguyen at the Royal Adelaide Hospital and by Professor Holtmann at the Princess Alexandra Hospital• Participants are eligible for compensation to cover the cost of time and travel
To learn more about this study:For Adelaide, please call: +61 8 7074 2188 or email: Joshua.Zobel@sa.gov.auFor Brisbane, please call: +61 7 3176 9190 or email: Teressa.Hansen@health.qld.gov.au
View the clinical trial brochure here.
Eosinophilic Oesophagitis Study
Griffith University are examining the effect of a new treatment in helping to reduce symptoms of eosinophilic oesophagitis. The trial is looking for adults across Australia and involves taking a new gel-based supplement for 12 weeks and monitoring your symptoms. By taking part you will have the opportunity to be involved in the latest research for eosinophilic oesophagitis.
Please contact Rebecca at immunology-research@griffith.edu.au or 0422 381 424 for further information.
Other opportunities to participate in research
EGID Partners
EGID Partners is an online cohort of patients with eosinophilic gastrointestinal diseases (EGIDs) brought to you in a collaboration between Patient Advocacy Groups and Researchers.
EGID Partners engages patients to help guide research. People without EGIDs are also encouraged to join so data can be compared. Together we can advance the care of conditions like eosinophilic esophagitis (EoE), eosinophilic gastritis (EoG), and eosinophilic colitis (EoC). ausEE Inc. is proud to be a patient advocacy group partner of EGID Partners.
Visit egidpartners.org to learn more and to become a Partner!
EGID Partners engages patients to help guide research. People without EGIDs are also encouraged to join so data can be compared. Together we can advance the care of conditions like eosinophilic esophagitis (EoE), eosinophilic gastritis (EoG), and eosinophilic colitis (EoC). ausEE Inc. is proud to be a patient advocacy group partner of EGID Partners.
Visit egidpartners.org to learn more and to become a Partner!
Join Us
Join Us is a simple online register that connects you with researchers to help prevent, treat and find cures for health conditions.
ausEE Inc. is proud to be a partner organisation of Join Us, working to strengthen Australia’s research capability and improve health and wellbeing for the whole community.
Sign up to be matched with research studies relevant to you at joinus.org.au.
Sign up to be matched with research studies relevant to you at joinus.org.au.
